touch ONCOLOGY

  • Home
  • touch ONCOLOGY

touch ONCOLOGY touchONCOLOGY.com hosts the expert content from peer-reviewed, free-to-access journals – EU Oncology

At touchONCOLOGY, we push the boundaries of online medical education to bring you innovative formats and valuable insights into learning behaviours. Our educational content enhances your ability to provide better patient care and drive positive change in clinical practice. With patients at the heart of everything we do, we aim to help you significantly improve health outcomes. This information is

intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

📢 Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: Where We’re At and Where It’s Heading“We’re moving toward high...
07/11/2025

📢 Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: Where We’re At and Where It’s Heading

“We’re moving toward higher cure rates – and potentially bladder preservation – with more effective systemic therapies.” – Dr Petros Grivas

In this exclusive ESMO 2025 interview, Dr Petros Grivas (University of Washington & Fred Hutchinson Cancer Center) shares his insights on the evolving landscape of neoadjuvant therapy for muscle-invasive bladder cancer.

He discusses key advances in:
🧬 Combination immunotherapy approaches
🧫 Biomarker-driven treatment personalisation
💧 Bladder preservation strategies

Discover where the field stands today – and where it’s heading next.

👉 Read more: https://touchoncology.com/insight/neoadjuvant-mi-bladder-cancer/

Have you seen our latest video?‘Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across di...
07/11/2025

Have you seen our latest video?

‘Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across disease stages’

Watch now: https://youtu.be/Wb_hNvyOH3k

🧬 Emerging Cell Therapy Approaches in Relapsed/Refractory AML in Older AdultsRelapsed or refractory acute myeloid leukae...
06/11/2025

🧬 Emerging Cell Therapy Approaches in Relapsed/Refractory AML in Older Adults

Relapsed or refractory acute myeloid leukaemia (AML) in older adults remains challenging due to high-risk disease features, comorbidities, and drug resistance.

This review explores:
🔹 Novel cell therapy approaches, including tailored haematopoietic stem cell transplantation
🔹 Strategies to improve tolerability and efficacy in older patients
🔹 Key considerations for integrating these therapies into clinical practice

📖 Read the full article:
https://touchoncology.com/haematology/journal-articles/emerging-cell-therapy-approaches-in-relapsed-refractory-acute-myeloid-leukaemia-in-older-adults/

💡 Advancements in Immunotherapy for ESCCImmune checkpoint inhibitors are transforming the management of oesophageal squa...
05/11/2025

💡 Advancements in Immunotherapy for ESCC

Immune checkpoint inhibitors are transforming the management of oesophageal squamous cell carcinoma.

Combining immunotherapy with chemotherapy is showing improved survival in advanced disease and higher response rates in locally advanced, resectable cases. These developments highlight the growing role of immunotherapy in ESCC and point toward future practice-changing strategies.

📖 Read more: https://touchoncology.com/gastrointestinal-cancers/journal-articles/advancements-in-immune-checkpoint-inhibitors-for-oesophageal-squamous-cell-carcinoma-current-status-and-future-perspectives/

🌟 Future Leader 2025 – Dr Elene Mariamidze 🌟Dr Elene Mariamidze (Todua Clinic, Tbilisi, Georgia) reflects on the mentors...
03/11/2025

🌟 Future Leader 2025 – Dr Elene Mariamidze 🌟

Dr Elene Mariamidze (Todua Clinic, Tbilisi, Georgia) reflects on the mentors who shaped her career, the resilience needed to thrive in oncology, and her advice for the next generation of oncologists.

With a research focus on thoracic malignancies, breast cancer and oncofertility, she shares candid insights into the realities of oncology – from the importance of global mentorship to building perseverance in a demanding yet rewarding field.

📖 Read more: https://touchoncology.com/insight/dr-elene-mariamidze-on-world-renowned-mentors-and-resilience-touchoncology-future-leader-2025/

🫁 Think Horses, But Do Not Forget the Zebras: Early-Onset Lung CancerLung cancer in individuals under 50 is rare but bio...
03/11/2025

🫁 Think Horses, But Do Not Forget the Zebras: Early-Onset Lung Cancer

Lung cancer in individuals under 50 is rare but biologically distinct. Unlike older patients, traditional risk factors may be absent — with environmental exposures and genetic predisposition playing a larger role.

Key points highlighted in this review:
🔹Young adults often present with advanced disease due to delayed diagnosis
🔹Higher prevalence of actionable oncogenic mutations supports comprehensive molecular profiling
🔹Targeted therapies and immunotherapies improve outcomes but may cause long-term toxicities
🔹Age-adapted treatment strategies, survivorship planning, and psychosocial support are crucial

Read the full review 👇
https://touchoncology.com/lung-cancer/journal-articles/think-horses-but-do-not-forget-the-zebras-early-onset-lung-cancer/

📘 touchREVIEWS in Oncology & Haematology – Volume 21, Issue 2 (2025) is out now!This latest issue features expert insigh...
31/10/2025

📘 touchREVIEWS in Oncology & Haematology – Volume 21, Issue 2 (2025) is out now!

This latest issue features expert insights across cancer care, including:
• Advances in therapies for advanced hepatocellular carcinoma
• The role of gut microbiota in cancer immunotherapy
• Evolving approaches in cervical cancer management
• Updates in thrombotic thrombocytopenic purpura
• The unique challenges of early-onset lung cancer

These articles highlight innovation and collaboration driving progress in oncology and haematology.

Read the full issue 👉
https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-21-issue-2-2025/

🩸 Advances in Thrombotic Thrombocytopenic Purpura TreatmentThrombotic thrombocytopenic purpura (TTP) is a rare, life-thr...
31/10/2025

🩸 Advances in Thrombotic Thrombocytopenic Purpura Treatment

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder where deficiency of ADAMTS13 leads to platelet aggregation and microvascular thrombosis.

This review explores:
• Current understanding of TTP pathophysiology and diagnosis
• Standard treatments and ongoing challenges with relapse and refractory disease
• Key clinical trials from the past 15 years evaluating adjuvant therapies for immune and congenital TTP

These insights highlight how emerging treatments may improve outcomes for patients living with this complex condition.

Read the review 👇
https://touchoncology.com/haematology/journal-articles/new-adjuvant-treatment-modalities-in-thrombotic-thrombocytopenic-purpura-a-review-of-recent-clinical-trials/

Revisited...🧠 Challenging decisions in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)?In this CME-accredited ac...
31/10/2025

Revisited...

🧠 Challenging decisions in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)?

In this CME-accredited activity, Dr Nabil Saba and Dr Victoria Villaflor guide you through three real-world R/M NPC cases, offering expert perspectives on:
🔍 Applying guidelines in practice
🔍 How EBV & PD-L1 status impact decisions
🔍 When to consider immune checkpoint inhibitors

💬 “The benefits of adding a checkpoint inhibitor outweigh the risks in most patients with metastatic nasopharyngeal cancer.” – Dr. Victoria Villaflor

👉 Gain practical insights you can use in clinic and earn CME credit today: https://touchoncologyime.org/treatment-selection-in-r-m-npc/

This activity is funded by an independent medical education grant from Coherus Biosciences.

This activity is jointly provided by USF Health and touchIME.

🎗️ Raising awareness saves livesEducation, advocacy, and early detection remain essential in the fight against breast ca...
30/10/2025

🎗️ Raising awareness saves lives

Education, advocacy, and early detection remain essential in the fight against breast cancer. Awareness month reminds us that every conversation, campaign, and action contributes to better outcomes—from encouraging screening to sharing knowledge on the latest treatment strategies.

Patients, healthcare providers, and communities all have a role in shaping the future of breast cancer care. Awareness initiatives not only support prevention and early detection but also highlight the importance of research, innovation, and access to care.

📌 Browse expert videos, short articles, and peer-reviewed research to stay informed:
https://touchoncology.com/speciality/breast-cancer/

Association of Cancer Care Centers

🩺 Frontline Therapy in Advanced Hepatocellular Carcinoma 🌐Hepatocellular carcinoma (HCC) remains a leading cause of canc...
30/10/2025

🩺 Frontline Therapy in Advanced Hepatocellular Carcinoma 🌐

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with most cases diagnosed at advanced stages requiring systemic treatment.

This review explores:
🔹Current frontline therapies, including targeted agents, tyrosine kinase inhibitors, and immunotherapy
🔹Evidence supporting combination regimens with immune checkpoint inhibitors over sorafenib
🔹Challenges such as treatment resistance and the need for predictive biomarkers
🔹Emerging approaches and ongoing research aiming to optimise outcomes for advanced HCC

Read the full analysis 👇
https://touchoncology.com/gastrointestinal-cancers/journal-articles/frontline-therapy-in-advanced-hepatocellular-carcinoma/

Address


Website

Alerts

Be the first to know and let us send you an email when touch ONCOLOGY posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to touch ONCOLOGY:

Shortcuts

  • Want your business to be the top-listed Media Company?

Share

Our Story

The information posted on this channel is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis or treatment recommendations.

touchONCOLOGY.com is an independent source of peer-reviewed content from our biannual journals – European Oncology & Haematology and Oncology & Hematology Review (US). Free to access, it is designed to support busy physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity. Concise and balanced articles authored by leading voices, are complemented by carefully curated video and podcasts.